Literature DB >> 11134664

The interface between pharmacoepidemiology and pharmacogenetics.

H G Leufkens.   

Abstract

One of the most challenging areas of research in pharmacoepidemiology is to understand why individuals respond differently to drug therapy, both in terms of beneficial and adverse effects. Pharmacogenetics focuses on the question to what extent variability in genetic make-up is responsible for these observed differences. Pharmacoepidemiologic research can contribute to pharmacogenetics by explaining the observed variability in drug response in 'real life' patient populations with known polymorphisms in their genetic profile. Genetic pharmacoepidemiologists also are interested in the distribution of polymorphisms and correlated frequencies of responders and non-responders in the general population, and in searching for unknown genetic links to variability in drug response. In the future, we will probably have fewer drugs that suit all individuals. Genetic pharmacoepidemiology is going to play a major role in the development and evaluation of the concept of 'tailor-made' pharmacotherapy.

Entities:  

Mesh:

Year:  2000        PMID: 11134664     DOI: 10.1016/s0014-2999(00)00810-4

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

Review 1.  Pharmacogenetics and the treatment of functional gastrointestinal disorders.

Authors:  Houssam Halawi; Michael Camilleri
Journal:  Pharmacogenomics       Date:  2017-07-07       Impact factor: 2.533

2.  Estimating heritability of glycaemic response to metformin using nationwide electronic health records and population-sized pedigree.

Authors:  Iris N Kalka; Amir Gavrieli; Smadar Shilo; Hagai Rossman; Nitzan Shalom Artzi; Nancy-Sarah Yacovzada; Eran Segal
Journal:  Commun Med (Lond)       Date:  2021-12-01

3.  Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma.

Authors:  Nadia Barahmani; Sarah Carpentieri; Xio-Nan Li; Tao Wang; Yumei Cao; Laura Howe; Lindsay Kilburn; Murali Chintagumpala; Ching Lau; M Fatih Okcu
Journal:  Neuro Oncol       Date:  2008-10-24       Impact factor: 12.300

4.  How to Transition from Single-Gene Pharmacogenetic Testing to Preemptive Panel-Based Testing: A Tutorial.

Authors:  Richard J Marrero; Emily J Cicali; Meghan J Arwood; Elizabeth Eddy; David DeRemer; Brian H Ramnaraign; Karen C Daily; Dennie Jones; Kelsey J Cook; Larisa H Cavallari; Kristin Wiisanen Weitzel; Taimour Langaee; Kimberly J Newsom; Petr Starostik; Michael J Clare-Salzer; Julie A Johnson; Thomas J George; Rhonda M Cooper-DeHoff
Journal:  Clin Pharmacol Ther       Date:  2020-07-06       Impact factor: 6.875

Review 5.  Genetic epidemiology of acute respiratory distress syndrome: implications for future prevention and treatment.

Authors:  Michelle Ng Gong
Journal:  Clin Chest Med       Date:  2006-12       Impact factor: 2.878

6.  Recruitment of participants through community pharmacies for a pharmacogenetic study of antihypertensive drug treatment.

Authors:  Diane B M A van Wieren-de Wijer; Anke-Hilse Maitland-van der Zee; Anthonius de Boer; Bruno H Ch Stricker; Abraham A Kroon; Peter W de Leeuw; O Bozkurt; Olaf H Klungel
Journal:  Pharm World Sci       Date:  2008-11-30

Review 7.  Pharmacogenetics of glucose-lowering drug treatment: a systematic review.

Authors:  Ozlem Bozkurt; Anthonius de Boer; Diederick E Grobbee; Eibert R Heerdink; Huib Burger; Olaf H Klungel
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.